Poster ASH 2016 - Safety Data from a First-in-Human Phase I Trial of NKG2D CAR-T Cells in AML/MDS & MM

Poster ASH 2016 - Safety Data from a First-in-Human Phase I Trial of NKG2D CAR-T Cells in AML/MDS & MM

Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting

Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting

Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium

Celyad announces third quarter 2016 business update

Celyad announces third quarter 2016 business update

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

Celyad responds to misleading statements on its patent relating to allogeneic human primary T-Cells that are engineered to be TCR-deficient and express a CAR

Celyad responds to misleading statements on its patent relating to allogeneic human primary T-Cells that are engineered to be TCR-deficient and express a CAR

Celyad's CYAD-01 therapy (previously named NKR-2)

Celyad's CYAD-01 therapy (previously named NKR-2)

How does the immune system fight cancer?

How does the immune system fight cancer?

What is cancer?

What is cancer?

NKR-2 Phase I Trial Safety Data in AML/MDS and MM presented at 2016 CAR-T Summit

NKR-2 Phase I Trial Safety Data in AML/MDS and MM presented at 2016 CAR-T Summit

Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa

Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level